Advanced

Epilepsy in Sweden: health care costs and loss of productivity-a register-based approach.

Bolin, Kristian LU ; Lundgren, Anders; Berggren, Fredrik and Källén, Kristina LU (2012) In European Journal of Health Economics 13(6). p.819-826
Abstract
PURPOSE:

The objective was to estimate health care costs and productivity losses due to epilepsy in Sweden and to compare these estimates to previously published estimates.



METHODS:

Register data on health care utilisation, pharmaceutical sales, permanent disability and mortality were used to calculate health care costs and costs that accrue due to productivity losses. By linkage of register information, we were able to distinguish pharmaceuticals prescribed against epilepsy from prescriptions that were prompted by other indications.



RESULTS:

The estimated total cost of epilepsy in Sweden in 2009 was <euro>441 million, which corresponds to an annual per-patient cost of... (More)
PURPOSE:

The objective was to estimate health care costs and productivity losses due to epilepsy in Sweden and to compare these estimates to previously published estimates.



METHODS:

Register data on health care utilisation, pharmaceutical sales, permanent disability and mortality were used to calculate health care costs and costs that accrue due to productivity losses. By linkage of register information, we were able to distinguish pharmaceuticals prescribed against epilepsy from prescriptions that were prompted by other indications.



RESULTS:

The estimated total cost of epilepsy in Sweden in 2009 was <euro>441 million, which corresponds to an annual per-patient cost of <euro>8,275. Health care accounted for about 16% of the estimated total cost, and drug costs accounted for about 7% of the total cost. The estimated health care cost corresponded to about 0.2% of the total health care cost in Sweden in 2009. Indirect costs were estimated at <euro>370 million, 84% of which was due to sickness absenteeism. Costs resulting from epilepsy-attributable premature deaths or permanent disability to work accounted for about 1% of the total indirect cost in Sweden in 2009.



DISCUSSION:

The per-patient cost of epilepsy is substantial. Thus, even though the prevalence of the illness is relatively small, the aggregated cost that epilepsy incurs on society is significant. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Health Economics
volume
13
issue
6
pages
819 - 826
publisher
Springer
external identifiers
  • wos:000313009800012
  • pmid:22042322
  • scopus:84870536145
ISSN
1618-7601
DOI
10.1007/s10198-011-0361-8
language
English
LU publication?
yes
id
4095fcb1-92ef-4f1c-92a6-e8060b5cc38a (old id 2221351)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22042322?dopt=Abstract
date added to LUP
2011-12-02 17:58:05
date last changed
2017-10-22 04:52:59
@article{4095fcb1-92ef-4f1c-92a6-e8060b5cc38a,
  abstract     = {PURPOSE:<br/><br>
The objective was to estimate health care costs and productivity losses due to epilepsy in Sweden and to compare these estimates to previously published estimates.<br/><br>
<br/><br>
METHODS:<br/><br>
Register data on health care utilisation, pharmaceutical sales, permanent disability and mortality were used to calculate health care costs and costs that accrue due to productivity losses. By linkage of register information, we were able to distinguish pharmaceuticals prescribed against epilepsy from prescriptions that were prompted by other indications.<br/><br>
<br/><br>
RESULTS:<br/><br>
The estimated total cost of epilepsy in Sweden in 2009 was &lt;euro&gt;441 million, which corresponds to an annual per-patient cost of &lt;euro&gt;8,275. Health care accounted for about 16% of the estimated total cost, and drug costs accounted for about 7% of the total cost. The estimated health care cost corresponded to about 0.2% of the total health care cost in Sweden in 2009. Indirect costs were estimated at &lt;euro&gt;370 million, 84% of which was due to sickness absenteeism. Costs resulting from epilepsy-attributable premature deaths or permanent disability to work accounted for about 1% of the total indirect cost in Sweden in 2009.<br/><br>
<br/><br>
DISCUSSION:<br/><br>
The per-patient cost of epilepsy is substantial. Thus, even though the prevalence of the illness is relatively small, the aggregated cost that epilepsy incurs on society is significant.},
  author       = {Bolin, Kristian and Lundgren, Anders and Berggren, Fredrik and Källén, Kristina},
  issn         = {1618-7601},
  language     = {eng},
  number       = {6},
  pages        = {819--826},
  publisher    = {Springer},
  series       = {European Journal of Health Economics},
  title        = {Epilepsy in Sweden: health care costs and loss of productivity-a register-based approach.},
  url          = {http://dx.doi.org/10.1007/s10198-011-0361-8},
  volume       = {13},
  year         = {2012},
}